نتایج جستجو برای: 5 fluorouracil colon cancer

تعداد نتایج: 2083830  

2010
Ludger Staib Marko Kornmann Karl-Heinrich Link

The FOGT (Study Group for GI-Oncology) was formed among clinicians and scientists with the aim of testing innovative scientific concepts in gastrointestinal tumors, especially colorectal cancers, within controlled clinical studies. In the FOGT-1 trial (n=813stage III or II(T4N0) colon cancer patients) the effect on recurrence-free and overall survivalwas tested by an adjuvant chemotherapy proto...

2015
Halyna M. Kuznietsova Valentyna K. Luzhenetska Iryna P. Kotlyar Volodymyr K. Rybalchenko

INTRODUCTION Pyrrol derivate 5-amyno-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrol-3-one (D1) has shown antiproliferative activities in vitro, so investigation of the impact of D1 intake on gut organs in rats that experienced colon cancer seems to be necessary. MATERIALS AND METHODS D1 at the dose of 2.3 mg/kg was administered per os daily for 27 (from the 1st day of exp...

Journal: :Anticancer research 2016
Jamie N Hadac Devon D Miller Ian C Grimes Linda Clipson Michael A Newton William R Schelman Richard B Halberg

BACKGROUND Despite receiving post-operative 5-fluorouracil (5-FU)-based chemotherapy, approximately 50% of patients with stage IIIC colon cancer experience recurrence. Currently, no molecular signature can predict response to 5-FU. MATERIALS AND METHODS Mouse models of colon cancer have been developed and characterized. Individual tumors in these mice can be longitudinally monitored and asses...

2005

1 Abad A, Garcia P, Gravalos C, et al. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial. Cancer 1995; 75: 1238–44. 2 Ajani JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A ran...

Journal: :Frontiers in Pharmacology 2021

Discovery of markers predictive for 5-Fluorouracil (5-FU)-based adjuvant chemotherapy (adjCTX) response in patients with locally advanced stage II and III colon cancer (CC) is necessary precise identification potential therapy responders. PEA3 subfamily ETS transcription factors (ETV1, ETV4, ETV5) are upregulated multiple cancers including cancers. However, the underlying epigenetic mechanism r...

Journal: :Molecules 2016
Cristina Di Donato Margherita Lavorgna Roberto Fattorusso Carla Isernia Marina Isidori Gaetano Malgieri Concetta Piscitelli Chiara Russo Luigi Russo Rosa Iacovino

Cyclodextrins are natural macrocyclic oligosaccharides able to form inclusion complexes with a wide variety of guests, affecting their physicochemical and pharmaceutical properties. In order to obtain an improvement of the bioavailability and solubility of 5-fluorouracil, a pyrimidine analogue used as chemotherapeutic agent in the treatment of the colon, liver, and stomac cancers, the drug was ...

2017
Cheng Wen Yao Kyoung Ah Kang Mei Jing Piao Yea Seong Ryu Pattage Madushan Dilhara Jayatissa Fernando Min Chang Oh Jeong Eon Park Kristina Shilnikova Soo-Young Na Seung Uk Jeong Sun-Jin Boo Jin Won Hyun

We investigated the role of autophagy in SNUC5/5-FUR, 5-fluorouracil (5-FU) resistant SNUC5 colon cancer cells. SNUC5/5- FUR cells exhibited low level of autophagy, as determined by light microscopy, confocal microscopy, and flow cytometry following acridine orange staining, and the decreased level of GFP-LC3 puncta. In addition, expression of critical autophagic proteins such as Atg5, Beclin-1...

2011
Liyi Geng Amelia M. Huehls Jill M. Wagner Catherine J. Huntoon Larry M. Karnitz

The fluoropyrimidines 5-fluorouracil (5-FU) and FdUrd (5-fluorodeoxyuridine; floxuridine) are the backbone of chemotherapy regimens for colon cancer and other tumors. Despite their widespread use, it remains unclear how these agents kill tumor cells. Here, we have analyzed the checkpoint and DNA repair pathways that affect colon tumor responses to 5-FU and FdUrd. These studies demonstrate that ...

2010
C.L. Attard J.A. Maroun K. Alloul D.T. Grima L.M. Bernard

OBJECTIVE The cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5FU/LV)-the FOLFOX regimen-was compared with that of 5FU/LV alone as adjuvant therapy for patients with stage III colon cancer, from the perspective of the Cancer Care Ontario New Drug Funding Program. In the mosaic (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuv...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید